254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY.
Saved in:
| Title: | 254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY. |
|---|---|
| Authors: | Thieblemont, C., Row, C., Lamy, T., Aucagne, R., Tani, M., Merli, M., Deodato, M., Usai, S. V., Minoia, C., Bommier, C., Fournier, C., Bijou, F., Pirosa, M. C., Anastasia, A., Devizzi, L., Luminari, S., Arcaini, L., Chevreux, S., Gressin, R., André, M., et al |
| Source: | Hematological oncology 2025 Supplement; Vol. 43. |
| Journal Info: | Publisher: Wiley-Blackwell ISSN: 0278-0232 |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1099-1069 |
|---|---|
| DOI: | 10.1002/hon.70094_254 |
